Agenus Inc (AGEN)

4.48
0.78 14.83
NASDAQ : Health Care
Prev Close 5.26
Open 5.05
Day Low/High 4.39 / 5.05
52 Wk Low/High 2.61 / 9.23
Volume 3.93M
Avg Volume 1.01M
Exchange NASDAQ
Shares Outstanding 99.12M
Market Cap 509.47M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Market's Trading Range Loosens Up

Market's Trading Range Loosens Up

Netflix is the star as S&P, Nasdaq set records.

Agenus Stock Sees Short Interest Decline 14.4%

Agenus Stock Sees Short Interest Decline 14.4%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,600,454 share decrease in total short interest for Agenus Inc , to 9,488,666, a decrease of 14.43% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Positive Phase 3 For GSK's Shingles Vaccine Shingrix With Agenus' QS-21 Stimulon® Immune Adjuvant

-GSK to present the revaccination study results at the CDC's Advisory Meeting on patients who had previously received standard of care treatment-

First Week of February 2018 Options Trading For Agenus (AGEN)

Investors in Agenus Inc saw new options begin trading this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Phase 1/2 Clinical Trial Of Agenus' Anti-PD-1 Antibody Begins

First patient dosed; combination trials with anti-PD-1 plus anti-CTLA-4 antibodies planned by year-end

Agenus Commences Phase 1 Trial With Neoantigen Cancer Vaccine AutoSynVax™

Two posters presented at AACR show evidence of ASV™ synergizing with checkpoint blockade

Agenus Restructures Business To Sharpen Focus On Clinical Development Of Cancer Therapies

- Will Host Conference Call at 9am ET Today -

First Week Of AGEN November 17th Options Trading

Investors in Agenus Inc saw new options become available this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

These 5 Stocks Under $10 Could Ignite Soon

These 5 Stocks Under $10 Could Ignite Soon

Here's a technical look at how to trade several under-$10 stocks that could break out soon.

Http://www.agenusbio.com

Incyte Corporation (Nasdaq:INCY) and Agenus Inc. (Nasdaq:AGEN) announced today that the companies have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015.

Short Interest In Agenus Expands By 11.5%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,286,223 share increase in total short interest for Agenus Inc , to 12,447,546, an increase of 11.52% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer

- Appointment signals clinical focus -

First Week Of AGEN August 2017 Options Trading

First Week Of AGEN August 2017 Options Trading

Investors in Agenus Inc saw new options become available this week, for the August 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of AGEN December 16th Options Trading

First Week of AGEN December 16th Options Trading

Investors in Agenus Inc saw new options become available this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new December 16th contracts and identified one put and one call contract of particular interest.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Technology stocks dominate the bearish ledger this week.

Interesting AGEN Put And Call Options For May 2017

Interesting AGEN Put And Call Options For May 2017

Investors in Agenus Inc saw new options begin trading this week, for the May 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

4 Momentum Stocks You Should Watch Now

4 Momentum Stocks You Should Watch Now

Here are four stocks to watch with strong technical momentum.

Notable Thursday Option Activity: AGEN, TWTR, RTRX

Notable Thursday Option Activity: AGEN, TWTR, RTRX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Agenus Inc , where a total of 9,287 contracts have traded so far, representing approximately 928,700 underlying shares. That amounts to about 87.1% of AGEN's average daily trading volume over the past month of 1.1 million shares.

Agenus Reports Second Quarter 2016 Financial Results And Operational Progress

Agenus Reports Second Quarter 2016 Financial Results And Operational Progress

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported...